Introduction {#sec1}
============

Rheumatoid arthritis (RA), a chronic systemic autoimmune disease distributed in all racial and ethnic groups, leads to joint stiffness, deformity and damage \[[@cit0001]\]. It is characterized by irreversible, alternating episodes, swelling, pain and tenderness, which results in worsening of physical condition, a reduction of life quality, a decline in employment and increasing direct or indirect expenses \[[@cit0002]\]. Based on recent statistics, the morbidity of patients with RA in developed countries was approximately 1% in the adult population \[[@cit0003]\]. Generally, the prevalence of RA in Asian countries was less than that in North America (1.1--1.6%) or in Northern Europe (0.4--0.8%) \[[@cit0004]\].

A number of drugs which were used in treating the patients with RA separately or together responded well. Among them, infliximab, etanercept, adalimumab, golimumab, tocilizumab, abatacept, certolizumab pegol, methotrexate, and conventional disease-modifying anti-rheumatic drugs (cDMARDs) were the most common choices \[[@cit0005]\]. A report showed that the difference between certolizumab pegol and placebo in the American College of Rheumatology 20% response rate (ACR20) was statistically significant from 1 week to 24 weeks. For example, the ACR20 was 45.5% for certolizumab pegol (400 mg every 4 weeks) compared to 9.3% for placebo at week 24 \[[@cit0006]\]. However, in order to minimize the risk of neutralizing antibodies and to enhance efficacy, biologic agents are combined with cDMARDs most of the time, though several biologic agents were applied as single therapy \[[@cit0007]\]. According to the studies, patients with RA treated with placebo plus methotrexate, golimumab (100 mg) plus placebo, golimumab (50 mg) plus methotrexate and golimumab (100 mg) plus methotrexate had ACR20 response rates of 33.1%, 44.4%, 55.1% and 56.2% respectively. Apparently, the therapy combining golimumab with methotrexate can significantly relieve the disease and improve the physical condition \[[@cit0008]\].

Up to now, there have been dozens of pair-wise meta-analyses (MA) and network meta-analyses (NMA) which evaluate the efficacy and safety of different drug therapies for patients with RA. Nevertheless, most of the trials only focused on two interventions or just a few kinds of drugs, and some of the initial MAs were contradicted by subsequent studies. For instance, a 55% increase in risk of serious infection for patients who were treated with biologics was reported by a Cochrane review \[[@cit0009]\], while another trial evaluating malignancy risk in RA patients concluded that there was no significant evidence of an increased risk of malignancy using biologics \[[@cit0010]\]. In contrast, Bongartz *et al.* reported that RA patients who were treated by anti-TNF therapies had an increased risk of serious infections and malignancies \[[@cit0011]\]. Therefore, although previous studies have shown abundant data and information, they just verified the efficacy or safety of various therapies for patients with RA. However, the lack of head-to-head comparisons and the absence of systematical comparison made the results incomplete and inconclusive.

An NMA seeks to infer the relative efficacy of two treatments by direct and indirect comparisons. Simultaneously, it extracts and analyzes data from all randomized control trials (RCTs) to select the best therapy \[[@cit0012]\]. Four efficacy outcomes and two safety outcomes were chosen to systematically assess 15 therapies from 56 RCTs with a sample size of 20,898 patients. The objective of the current study is to better characterize the efficacy and safety of each treatment for patients with RA and then make the best choice in clinical practice.

Material and methods {#sec2}
====================

Search strategy {#sec2.1}
---------------

We performed a systematic literature search in electronic databases, including PubMed, Embase and Cochrane Library, to retrieve eligible RCTs from 1997 to 2016. Key words and subject terms included "rheumatoid arthritis", "biological factors", "anti-TNF agents", "infliximab", "etanercept", "adalimumab", "golimumab", "certolizumab pegol", and "rituximab". Two reviewers performed the initial search, and all references were reviewed to identify additional studies that were not included in the retrieval. After that, they screened the titles and abstracts to make sure that the studies met predefined selection criteria individually.

Inclusion and exclusion criteria {#sec2.2}
--------------------------------

Studies included should meet the following criteria: (1) the study design should be RCT; (2) the trials included at least one pairwise comparison between two interventions, which should be used to treat patients with RA; (3) detailed data of at least one relevant outcome were provided. In addition, we excluded duplicate data, reviews, meeting or conference abstracts and case reports from the current analysis.

Outcome measurement and data extraction {#sec2.3}
---------------------------------------

The information as follows was extracted from each eligible study: study code, first author, year of publication, country in which the study was conducted, length of follow-up, interventions, sample size of each therapy and respective outcomes for efficacy and safety. There were 6 outcome indicators to assess the efficacy and safety. American College of Rheumatology 20%, 50%, and 70% response rate (ACR20, ACR50 and ACR70, defined as a 20%, 50% and 70% improvement in patients) at 12--54 weeks and remission were the efficacy outcomes. Among them, the primary efficacy endpoints were ACR20 and ACR50, and the secondary endpoints were ACR70 and remission. Meanwhile, adverse events (AEs) and serious adverse events (SAEs) were safety outcomes.

Statistical analysis {#sec2.4}
--------------------

The indirect and direct evidence from a wide range of data was analyzed through a Bayesian NMA. After each pair-wise comparison was conducted, the network diagrams of ACR20, ACR50, ACR70, remission, AEs and SAEs were plotted with different interventions. The size of circles indicated the quantity of specific interventions and the boldness of arms showed the number of included studies. The results of these binary variables were presented as odds ratios (ORs) with corresponding 95% credible intervals (CrIs). In addition, net heat plots and node-splitting test were used to analyze the inconsistency level between indirect and direct evidence. The rank probabilities of efficacy and safety of 15 therapies were assessed using surface under the cumulative ranking curve (SUCRA), and the Jadad scale was used to evaluate the methodological quality of eligible studies. All statistical analyses were implemented by STATA version 12.0.

Results {#sec3}
=======

Studies included in the network meta-analysis {#sec3.1}
---------------------------------------------

According to a systematic literature search in electronic databases, a total of 8,104 records were identified. Among them, 1,465 duplicate publications and 6,394 articles were excluded due to their irrelevant titles and abstracts. The remaining 245 articles were selected for full-text review and 178 articles assessed as ineligible were excluded. Eventually, 67 RCTs dating from 1997 to 2016 met the inclusion criteria with 20,898 patients \[[@cit0013]--[@cit0079]\]. The searching and selection steps are shown in [Figure 1](#f0001){ref-type="fig"}.

![Flow diagram of study inclusion](AMS-15-31923-g001){#f0001}

Characteristics of included studies {#sec3.2}
-----------------------------------

The characteristics of included trials are shown in [Table I](#t0001){ref-type="table"}. In detail, 33 of 56 different trials covered patients around the world and 15 trials included patients predominantly from Asia. The rest of the trials were reported to include patients from Europe (5 studies) and America (3 studies). The length of follow-up ranged from 12 to 54 weeks. Most of the trials included a comparison between two interventions. Only 5 trials mentioned comparisons among three interventions. All trials involved 10 drugs as follows: infliximab (INF), etanercept (ETN), adalimumab (ADA), golimumab (GOL), tocilizumab (TCZ), abatacept (ABT), certolizumab pegol (CZP), methotrexate (MTX), conventional disease-modifying anti-rheumatic drugs (cDMARDs) and placebo (PBO). The full network of comparisons categorized in different outcomes was shown in [Figure 2](#f0002){ref-type="fig"}.

###### 

Patient characteristics in the studies included in the mixed-treatment comparison (MTC) analysis

  No.         Study                   Author (year)                           Country         Follow-up \[weeks\]   Sizes   Intervention 1   Intervention 2   Outcomes          
  ----------- ----------------------- --------------------------------------- --------------- --------------------- ------- ---------------- ---------------- ----------- ----- --------
  1           Abe06                   Abe (2006)                              Japan           14                    137     cDMARDs          47               IFX + MTX   90    ①②③⑤⑥
  2           APPEAL                  Bae (2013) and Kim (2012)               Asia            16                    300     ETN + MTX        197              cDMARDs     103   ①②③④⑤⑥
  3           Combe06&09              Combe (2009) and Combe (2006)           Finland         24                    254     cDMARDs          50               ETN         103   ①②③⑤⑥
  ETN + MTX   101                                                                                                                                                               
  4           ACT-RAY                 Dougados (2013)                         UK              24                    553     TCZ + MTX        277              TCZ         276   ①②③④⑤⑥
  5           JESMR                   Kameda (2010)                           Japan           24                    142     ETN              69               ETN + MTX   73    ①②③④⑤⑥
  6           RED-SEA                 Jobanputra (2012)                       UK              52                    120     ADA              60               ETN         60    ⑥
  7           Kay08                   Kay (2008)                              Global          16                    171     cDMARDs          35               GOL + MTX   136   ①②③④⑤⑥
  8           Kim07                   Kim (2007)                              Korean          24                    128     cDMARDs          63               ADA + MTX   65    ①②③⑤⑥
  9           LITHE                   Kremer (2011)                           Global          52                    1190    cDMARDs          393              TCZ + MTX   797   ①②③④
  10          AIM                     Kremer (2006)                           Global          26                    652     ABT + MTX        433              cDMARDs     219   ①②③④⑤⑥
  11          Lan04                   Lan (2004)                              Taiwan          12                    58      ETN + MTX        29               cDMARDs     29    ①②③⑤
  12          Mathias00& Moreland99   Mathias (2000) and Moreland (1999)      North-America   26                    234     PBO              80               ETN         154   ①②③
  13          CHANGE                  Miyasaka (2008)                         Japan           24                    352     PBO              87               ADA         265   ①②③⑤⑥
  14          SAMURAI                 Nishimoto (2007)                        Japan           52                    302     cDMARDs          145              TCZ         157   ①②③④⑤⑥
  15          O'Dell2013              O'Dell (2013) and O'Dell (2012)         Global          48                    353     cDMARDs          178              ETN + MTX   175   ①②③④⑤⑥
  16          SATORI                  Nishimoto (2009)                        Japan           24                    125     TCZ + MTX        61               cDMARDs     64    ①②③④⑤⑥
  17          GO-FORTH                Tanaka (2012)                           Japan           24                    261     cDMARDs          88               GOL + MTX   173   ①②③④⑤⑥
  18          ATTEST                  Schiff (2008)                           Global          27                    321     ABT + MTX        156              IFX + MTX   165   ①②③④⑤⑥
  19          ADORE                   VanRiel (2006) and VanRiel (2008)       Europe          16                    314     ETN              159              ETN + MTX   155   ①②③④⑤⑥
  20          AUGUSTII                Van Vollenhoven (2011)                  Global          26                    311     PBO              76               ADA         79    ①②③⑤⑥
  ABT         156                                                                                                                                                               
  21          ARMADA                  Weinblatt (2003) and Weinblatt (2006)   North-America   24                    271     cDMARDs          62               ADA + MTX   209   ①②③
  22          START                   Westhovens (2006)                       Global          22                    1084    cDMARDs          363              IFX + MTX   721   ①②③④⑤⑥
  23          Zhang2006               Zhang (2006)                            China           18                    173     IFX + MTX        87               cDMARDs     86    ①②③⑤
  24          CREATEIIB               Keystone (2012)                         Global          26                    129     cDMARDs          65               ETN + MTX   64    ①②③⑤⑥
  25          CERTAIN                 Smolen (2011)                           Global          24                    194     cDMARDs          98               CZP + MTX   96    ①②③⑤⑥
  26          ADACTA                  Gabay (2013)                            Global          24                    325     TCZ              163              ADA         162   ①②③④
  27          TOWARD                  Genovese (2008)                         Global          24                    1216    TCZ + MTX        803              cDMARDs     413   ①②③④⑤⑥
  28          HIKARI                  Yamamoto (2014)                         Japan           24                    230     PBO              114              CZP         116   ①②③④⑤⑥
  29          AMPLE                   Schiff (2014) and Weinblatt (2014)      Global          52                    646     ABT + MTX        318              ADA + MTX   328   ①②③④⑤⑥
  30          GO-FURTHER              Weinblatt (2013)                        Global          24                    592     cDMARDs          197              GOL + MTX   395   ①②③⑤⑥
  31          Fleischmann 2012        Fleischmann (2012)                      Global          24                    112     PBO              59               ADA         53    ①②③⑤⑥
  32          Choy 2012               Choy (2012)                             Global          24                    247     CZP + MTX        126              cDMARDs     121   ①②③⑤⑥
  33          RAPID-II                Smolen (2009) and Strand (2011)         Global          24                    619     cDMARDs          127              CZP + MTX   492   ①②③⑤⑥
  34          GO-FORWARD              Keystone (2009)                         Global          14                    444     cDMARDs          133              GOL         133   ①②③④⑤⑥
  GOL + MTX   178                                                                                                                                                               
  35          Chen 2009               Chen (2009)                             Taiwan          14                    47      ADA + MTX        35               cDMARDs     12    ①②③⑤⑥
  36          FAST4WARD               Fleischmann (2009)                      Global          24                    220     PBO              109              CZP         111   ①②③⑤⑥
  37          Moreland 1997           Moreland (1997)                         Global          12                    180     PBO              44               ETN         136   ①②
  38          OPTION                  Smolen (2008)                           Global          16                    622     TCZ + MTX        418              cDMARDs     204   ①②③④⑤⑥
  39          RAPIDI                  Keystone (2008)                         Global          52                    982     cDMARDs          199              CZP + MTX   783   ①②③
  40          CHARISMA                Maini (2006)                            Europe          20                    359     TCZ              159              TCZ + MTX   151   ①②③⑤⑥
  cDMARDs     49                                                                                                                                                                
  41          VandePutte 2004         VandePutte (2004)                       Global          26                    544     ADA              434              PBO         110   ①②③⑤⑥
  42          TEMPO                   Klareskog (2004)                        Global          52                    682     cDMARDs          228              ETN         223   ①②③⑤⑥
  ETN + MTX   231                                                                                                                                                               
  43          VandePutte 2003         VandePutte (2003)                       Global          12                    284     PBO              70               ADA         214   ①②③⑥
  44          ATTRACT                 Lipsky (2000) and Maini (1999)          Global          54                    428     cDMARDs          88               IFX + MTX   340   ①②③⑥
  45          Kremer 2003             Kremer (2003)                           Global          26                    339     cDMARDs          119              ABT + MTX   220   ①②③⑥
  46          Chen 2016               Chen (2016)                             China           12                    358     ETN + MTX        239              cDMARDs     119   ①②③⑤⑥
  47          J-RAPID                 Yamamoto (2014)                         Japan           24                    316     cDMARDs          77               CZP + MTX   239   ①②③⑤⑥
  48          LatinRA                 Machado (2014) and Fleischmann (2014)   Latin America   24                    423     ETN + MTX        281              cDMARDs     142   ①②③④⑤⑥
  49          BREVACTA                Kivitz (2014) and Kivitz (2013)         Global          24                    656     TCZ              437              PBO         219   ①②③⑤⑥
  50          Hobbs 2015              Hobbs (2015)                            Global          12                    210     PBO              104              ETN         106   ①②③⑤⑥
  51          Li 2015                 Li (2015)                               China           14                    264     cDMARDs          132              GOL + MTX   132   ①②③④⑤⑥
  52          ASSET                   Conaghan (2013)                         Global          16                    50      ABT + MTX        27               cDMARDs     23    ④⑤⑥
  53          Keystone 2004           Keystone (2004)                         Global          24                    619     ADA + MTX        419              cDMARDs     200   ①②③⑤
  54          deFilippis 2006         DeFilippis (2006)                       Global          22                    30      ETN + MTX        15               IFX + MTX   15    ①②③
  55          Weinblatt 1999          Weinbaltt (1999)                        Global          24                    89      cDMARDs          30               ETN + MTX   59    ①②③
  56          STAR                    Furst (2003)                            Global          24                    636     ADA + MTX        318              cDMARDs     318   ③⑤⑥

PBO -- placebo, MTX -- methotrexate, IFX -- infliximab, ETN -- etanercept, ADA -- adalimumab, GOL -- golimumab, TCZ -- tocilizumab, ABT -- abatacept, CZP -- clonazepam, cDMARDs -- traditional synthetic disease modifying antirheumatic drugs, ACR -- American College of Rheumatology, AEs -- adverse events, SAEs -- serious adverse events.

Outcomes: ① -- ACR20 20% response rate, ② -- ACR50 50% response rate, ③ -- ACR70 70% response rate, ④ -- Remission, ⑤ -- AEs, ⑥ -- SAEs.

![Full network of comparisons categorized in different outcomes. The width of the lines is proportional to the number of trials comparing each pair of treatments; the area of circles represents the cumulative number of patients for each intervention](AMS-15-31923-g002){#f0002}

American College of Rheumatology 20% response rate (ACR20) {#sec3.3}
----------------------------------------------------------

ACR20 was normally defined as a 20% improvement for patients with rheumatoid arthritis. The estimated ORs with 95% CrIs of ACR20 for each comparison are shown in the lower panel of [Table II](#t0002){ref-type="table"}. Among these 15 therapies, ABT + MTX (OR = 5.42, 95% CrI: 2.12--14.0), ADA (OR = 4.31, 95% CrI: 2.53--7.39), ADA + MTX (OR = 5.81, 95% CrI: 2.39--14.7), CZP (OR = 11.3, 95% CrI: 4.48--28.8), CZP + MTX (OR = 9.68, 95% CrI: 3.86--24.5), ETN (OR = 4.22, 95% CrI: 2.23--8.17), ETN + MTX (OR = 6.31, 95% CrI: 3.10--14.0), GOL + MTX (OR = 6.23, 95% CrI: 2.46--15.6), INF + MTX (OR = 5.75, 95% CrI: 2.39--14.1), TCZ (OR = 5.64, 95% CrI: 2.8--11.47) and TCZ + MTX (OR = 7.10, 95% CrI: 3.16--16.1) revealed superior efficacy under the endpoint of ACR20 compared with PBO. In addition, CZP + MTX was more efficacious than ETN when comparing ACR20 (OR = 2.29, 95% CrI: 1.03--5.10).

###### 

Odds ratio estimates with 95% credible intervals of ACR20 and ACR50 for each comparison

  Endpoint    ACR50                                                                                                                                                                                                                                                                                                       
  ----------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  ACR20       ABT                 ABT                 0.47 (0.13, 1.72)   0.66 (0.24, 1.73)   0.38 (0.11, 1.36)   1.79 (0.55, 5.81)   0.30 (0.07, 1.21)   0.31 (0.09, 1.14)   0.70 (0.22, 2.27)   0.44 (0.13, 1.45)   0.76 (0.16, 3.63)   0.41 (0.11, 1.52)   0.48 (0.13, 1.72)   3.35 (1.22, 9.21)   0.44 (0.14, 1.39)   0.34 (0.10, 1.14)
  ABT + MTX   0.28 (0.07, 1.13)   ABT + MTX           1.40 (0.54, 3.53)   0.82 (0.44, 1.52)   3.82 (2.29, 6.42)   0.64 (0.18, 2.32)   0.66 (0.32, 1.40)   1.52 (0.72, 3.13)   0.94 (0.49, 1.77)   1.63 (0.52, 5.05)   0.89 (0.41, 1.88)   1.03 (0.53, 1.93)   7.17 (3.06, 17.0)   0.95 (0.44, 2.03)   0.73 (0.36, 1.45)   
  ADA         0.35 (0.12, 1.03)   1.27 (0.45, 3.53)   ADA                 0.58 (0.23, 1.48)   2.72 (1.26, 6.11)   0.46 (0.15, 1.36)   0.48 (0.18, 1.25)   1.08 (0.50, 2.32)   0.68 (0.30, 1.49)   1.16 (0.32, 4.22)   0.63 (0.24, 1.67)   0.73 (0.30, 1.86)   5.10 (3.03, 8.85)   0.68 (0.34, 1.39)   0.52 (0.23, 1.20)   
  ADA + MTX   0.26 (0.06, 1.02)   0.93 (0.47, 1.86)   0.73 (0.27, 1.97)   ADA + MTX           4.71 (2.89, 7.69)   0.79 (0.22, 2.83)   0.82 (0.39, 1.70)   1.86 (0.90, 3.78)   1.16 (0.62, 2.14)   1.99 (0.65, 6.17)   1.08 (0.52, 2.25)   1.26 (0.64, 2.46)   8.85 (3.78, 20.7)   1.16 (0.55, 2.46)   0.89 (0.45, 1.75)   
  cDMARDs     0.89 (0.24, 3.22)   3.22 (1.80, 5.75)   2.53 (1.09, 5.87)   3.46 (2.05, 5.87)   cDMARDs             0.17 (0.05, 0.54)   0.17 (0.10, 0.30)   0.39 (0.23, 0.66)   0.25 (0.17, 0.35)   0.43 (0.15, 1.16)   0.23 (0.13, 0.39)   0.27 (0.16, 0.43)   1.86 (0.94, 3.71)   0.25 (0.14, 0.44)   0.19 (0.12, 0.30)   
  CZP         0.13 (0.03, 0.55)   0.49 (0.13, 1.82)   0.38 (0.13, 1.12)   0.52 (0.14, 1.88)   0.15 (0.05, 0.49)   CZP                 1.04 (0.28, 3.82)   2.36 (0.74, 7.39)   1.48 (0.45, 4.85)   2.53 (0.53, 12.2)   1.38 (0.38, 5.05)   1.60 (0.45, 5.70)   11.1 (4.35, 29.7)   1.48 (0.47, 4.76)   1.13 (0.34, 3.86)   
  CZP + MTX   0.15 (0.04, 0.63)   0.56 (0.25, 1.25)   0.44 (0.16, 1.21)   0.60 (0.28, 1.30)   0.17 (0.10, 0.30)   1.16 (0.32, 4.26)   CZP + MTX           2.27 (1.07, 4.76)   1.42 (0.73, 2.72)   2.46 (0.76, 7.77)   1.34 (0.61, 2.86)   1.54 (0.75, 3.16)   10.8 (4.53, 26.1)   1.42 (0.66, 3.13)   1.08 (0.54, 2.23)   
  ETN         0.35 (0.10, 1.23)   1.28 (0.57, 2.92)   1.02 (0.45, 2.25)   1.38 (0.63, 3.03)   0.40 (0.22, 0.71)   2.66 (0.86, 8.25)   2.29 (1.03, 5.10)   ETN                 0.63 (0.39, 0.99)   1.07 (0.34, 3.39)   0.58 (0.28, 1.25)   0.68 (0.34, 1.38)   4.71 (2.56, 9.12)   0.63 (0.32, 1.25)   0.48 (0.25, 0.94)   
  ETN + MTX   0.23 (0.06, 0.84)   0.84 (0.41, 1.68)   0.66 (0.28, 1.55)   0.90 (0.46, 1.73)   0.26 (0.17, 0.39)   1.73 (0.52, 5.70)   1.49 (0.75, 2.94)   0.65 (0.37, 1.13)   ETN + MTX           1.73 (0.59, 5.16)   0.93 (0.49, 1.82)   1.08 (0.61, 1.97)   7.54 (3.82, 15.6)   1.00 (0.54, 1.95)   0.76 (0.44, 1.39)   
  GOL         0.46 (0.09, 2.41)   1.67 (0.48, 5.58)   1.31 (0.33, 5.16)   1.79 (0.54, 5.87)   0.51 (0.18, 1.51)   3.42 (0.69, 17.1)   2.94 (0.89, 9.87)   1.28 (0.38, 4.39)   1.97 (0.63, 6.36)   GOL                 0.54 (0.20, 1.45)   0.63 (0.20, 1.93)   4.39 (1.31, 15.2)   0.58 (0.19, 1.86)   0.44 (0.15, 1.36)   
  GOL + MTX   0.24 (0.06, 0.98)   0.88 (0.39, 1.95)   0.69 (0.25, 1.90)   0.94 (0.44, 2.03)   0.27 (0.16, 0.47)   1.82 (0.50, 6.69)   1.57 (0.72, 3.42)   0.68 (0.31, 1.54)   1.05 (0.53, 2.10)   0.53 (0.18, 1.55)   GOL + MTX           1.16 (0.57, 2.39)   8.08 (3.39, 19.7)   1.07 (0.50, 2.36)   0.82 (0.41, 1.70)   
  IFX + MTX   0.26 (0.07, 1.02)   0.94 (0.46, 1.93)   0.75 (0.28, 1.97)   1.01 (0.49, 2.10)   0.29 (0.18, 0.49)   1.95 (0.55, 7.03)   1.68 (0.79, 3.56)   0.73 (0.34, 1.58)   1.13 (0.60, 2.14)   0.57 (0.17, 1.90)   1.07 (0.51, 2.29)   IFX + MTX           7.03 (3.06, 16.1)   0.92 (0.44, 1.95)   0.70 (0.37, 1.38)   
  PBO         1.49 (0.51, 4.44)   5.42 (2.12, 14.0)   4.31 (2.53, 7.39)   5.81 (2.39, 14.7)   1.68 (0.81, 3.56)   11.3 (4.48, 28.8)   9.68 (3.86, 24.5)   4.22 (2.23, 8.17)   6.49 (3.10, 14.0)   3.29 (0.89, 12.3)   6.23 (2.46, 15.6)   5.75 (2.39, 14.1)   PBO                 0.13 (0.07, 0.25)   0.10 (0.05, 0.21)   
  TCZ         0.26 (0.08, 0.93)   0.97 (0.41, 2.27)   0.76 (0.35, 1.63)   1.04 (0.46, 2.36)   0.30 (0.16, 0.56)   1.99 (0.63, 6.42)   1.73 (0.76, 3.97)   0.75 (0.36, 1.57)   1.15 (0.58, 2.34)   0.58 (0.17, 2.01)   1.11 (0.48, 2.51)   1.03 (0.46, 2.29)   0.18 (0.09, 0.36)   TCZ                 0.76 (0.43, 1.35)   
  TCZ + MTX   0.21 (0.06, 0.79)   0.76 (0.35, 1.65)   0.61 (0.24, 1.48)   0.82 (0.40, 1.72)   0.24 (0.14, 0.39)   1.58 (0.46, 5.42)   1.36 (0.64, 2.89)   0.59 (0.29, 1.25)   0.91 (0.49, 1.73)   0.46 (0.14, 1.51)   0.88 (0.41, 1.84)   0.81 (0.39, 1.67)   0.14 (0.06, 0.32)   0.79 (0.41, 1.52)   TCZ + MTX           

PBO -- placebo, MTX -- methotrexate, IFX -- infliximab, ETN -- etanercept, ADA -- adalimumab, GOL -- golimumab, TCZ -- tocilizumab, ABT -- abatacept, CZP -- clonazepam, cDMARDs -- traditional synthetic disease modifying antirheumatic drugs, ACR -- American College of Rheumatology, AEs -- adverse events, SAEs -- serious adverse events.

American College of Rheumatology 50% response rate (ACR50) {#sec3.4}
----------------------------------------------------------

Base on the upper panel of [Table II](#t0002){ref-type="table"}, PBO showed the worst performance for ACR50 compared with all therapies except cDMARDs (OR = 1.86, 95% CrI: 0.94--3.71). As for cDMARDs, it revealed worse efficacy than the other treatments except ABT, GOL and PBO. In addition, ETN + MTX, CZP + MTX and TCZ + MTX were superior to ETN for the efficacy of ACR50 (ETN + MTX: OR = 1.59, 95% CrI: 1.01--2.56; CZP + MTX: OR = 2.27, 95% CrI: 1.07--4.76; TCZ + MTX: OR = 2.10, 95% CrI: 1.06--4.01.

American College of Rheumatology 70% response rate (ACR70) {#sec3.5}
----------------------------------------------------------

As shown in the lower panel of [Table III](#t0003){ref-type="table"}, only cDMARDs (OR = 2.41, 95% CrI: 0.91--7.10) demonstrated no statistically significant difference from PBO. Similarly, all the therapies appeared superior to cDMARDs when comparing ACR70, except for ABT (OR = 1.60, 95% CrI: 0.32--7.54), ADA (OR = 2.77, 95% CrI: 0.93--8.08) and GOL (OR = 2.69, 95% CrI: 0.37--10.3) Additionally, CZP enjoyed obvious superiority to ABT (OR = 0.05, 95% CrI: 0.01--0.62) and ADA (OR = 0.09, 95% CrI: 0.01--0.84).

###### 

Odds ratio estimates with 95% credible intervals of ACR70 and remission for each comparison

  Endpoint    Remission                                                                                                                                                                                                                                                                                                   
  ----------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  ACR70       ABT + MTX           0.30 (0.05, 1.60)   ABT + MTX           0.34 (0.02, 6.11)   0.90 (0.12, 6.75)   4.06 (1.03, 16.3)   --                  --                  2.10 (0.20, 23.8)   1.19 (0.18, 7.61)   1.17 (0.09, 13.2)   0.71 (0.12, 4.06)   1.06 (0.20, 5.58)   --                  0.06 (0.01, 0.45)   0.15 (0.03, 0.87)
  ADA         0.58 (0.17, 1.93)   1.90 (0.55, 6.96)   ADA                 2.69 (0.08, 107)    12.1 (0.92, 185)    --                  --                  6.17 (0.26, 183)    3.53 (0.21, 70.1)   3.49 (0.12, 104)    2.14 (0.13, 38.1)   3.16 (0.17, 68.7)   --                  0.17 (0.02, 1.39)   0.46 (0.03, 6.42)   
  ADA + MTX   0.30 (0.05, 1.55)   0.97 (0.45, 2.12)   0.51 (0.14, 1.73)   ADA + MTX           4.53 (0.39, 52.5)   --                  --                  2.34 (0.10, 54.1)   1.32 (0.08, 20.5)   1.32 (0.05, 30.0)   0.80 (0.05, 11.3)   1.20 (0.09, 16.4)   --                  0.06 (0.01, 1.12)   0.17 (0.01, 2.41)   
  cDMARDs     1.60 (0.32, 7.54)   5.26 (2.77, 10.4)   2.77 (0.93, 8.08)   5.42 (2.92, 10.5)   cDMARDs             --                  --                  0.52 (0.08, 3.63)   0.29 (0.08, 0.98)   0.29 (0.03, 2.10)   0.18 (0.06, 0.50)   0.26 (0.06, 1.09)   --                  0.02 (0.01, 0.07)   0.04 (0.01, 0.11)   
  CZP         0.05 (0.01, 0.62)   0.18 (0.01, 1.97)   0.09 (0.01, 0.84)   0.18 (0.01, 2.05)   0.03 (0.01, 0.34)   CZP                 --                  --                  --                  --                  --                  --                  --                  --                  --                  
  CZP + MTX   0.21 (0.04, 1.23)   0.70 (0.25, 2.05)   0.37 (0.10, 1.43)   0.73 (0.26, 2.08)   0.13 (0.06, 0.30)   3.97 (0.34, 133)    CZP + MTX           --                  --                  --                  --                  --                  --                  --                  --                  
  ETN         0.49 (0.09, 2.34)   1.62 (0.61, 4.06)   0.85 (0.25, 2.53)   1.65 (0.63, 4.06)   0.31 (0.15, 0.58)   9.03 (0.86, 276)    2.29 (0.75, 6.36)   ETN                 0.57 (0.12, 2.53)   0.57 (0.03, 9.03)   0.34 (0.04, 3.00)   0.51 (0.04, 5.53)   --                  0.03 (0.01, 0.32)   0.07 (0.01, 0.64)   
  ETN + MTX   0.31 (0.06, 1.49)   1.03 (0.44, 2.32)   0.54 (0.16, 1.63)   1.06 (0.46, 2.32)   0.20 (0.11, 0.31)   5.75 (0.55, 179)    1.46 (0.53, 3.71)   0.64 (0.36, 1.15)   ETN + MTX           1.00 (0.09, 10.2)   0.61 (0.11, 3.06)   0.90 (0.13, 5.87)   --                  0.05 (0.01, 0.34)   0.13 (0.02, 0.65)   
  GOL         0.59 (0.07, 4.71)   1.97 (0.44, 8.94)   1.04 (0.18, 5.81)   2.01 (0.47, 9.03)   0.37 (0.10, 1.42)   11.4 (0.75, 424)    2.80 (0.57, 13.3)   1.22 (0.28, 5.75)   1.90 (0.47, 8.41)   GOL                 0.61 (0.09, 4.48)   0.90 (0.08, 11.7)   --                  0.05 (0.01, 0.66)   0.13 (0.01, 1.36)   
  GOL + MTX   0.33 (0.05, 1.82)   1.08 (0.40, 2.97)   0.57 (0.15, 2.10)   1.12 (0.41, 2.97)   0.21 (0.09, 0.43)   6.17 (0.52, 198)    1.54 (0.50, 4.57)   0.68 (0.25, 1.92)   1.05 (0.43, 2.66)   0.55 (0.15, 1.93)   GOL + MTX           1.48 (0.25, 9.30)   --                  0.08 (0.01, 0.55)   0.22 (0.05, 0.98)   
  IFX + MTX   0.36 (0.06, 1.86)   1.19 (0.52, 2.66)   0.62 (0.17, 2.12)   1.21 (0.51, 2.86)   0.22 (0.12, 0.41)   6.69 (0.59, 211)    1.67 (0.58, 4.66)   0.73 (0.30, 1.86)   1.14 (0.53, 2.59)   0.60 (0.13, 2.56)   1.08 (0.41, 2.86)   IFX + MTX           --                  0.05 (0.01, 0.44)   0.15 (0.02, 0.86)   
  PBO         3.86 (1.07, 14.6)   12.8 (4.01, 46.5)   6.69 (3.35, 14.7)   13.1 (4.14, 47.0)   2.41 (0.91, 7.10)   70.8 (9.49, 1900)   18.0 (5.10, 69.4)   7.92 (2.94, 26.1)   12.3 (4.53, 40.4)   6.49 (1.23, 37.3)   11.7 (3.46, 45.6)   10.8 (3.46, 38.8)   PBO                                                         
  TCZ         0.39 (0.09, 1.70)   1.30 (0.50, 3.67)   0.68 (0.28, 1.75)   1.32 (0.52, 3.71)   0.24 (0.12, 0.53)   7.32 (0.77, 217)    1.82 (0.64, 5.64)   0.80 (0.34, 2.27)   1.25 (0.56, 3.25)   0.65 (0.15, 3.16)   1.19 (0.43, 3.63)   1.09 (0.44, 3.03)   0.10 (0.04, 0.24)   TCZ                 2.66 (0.57, 13.5)   
  TCZ + MTX   0.26 (0.05, 1.26)   0.86 (0.36, 2.12)   0.45 (0.15, 1.36)   0.88 (0.38, 2.14)   0.16 (0.09, 0.29)   4.85 (0.48, 148)    1.22 (0.45, 3.32)   0.53 (0.23, 1.35)   0.84 (0.41, 1.90)   0.44 (0.10, 1.92)   0.79 (0.31, 2.12)   0.73 (0.32, 1.79)   0.07 (0.02, 0.19)   0.67 (0.32, 1.32)   TCZ + MTX           

PBO -- placebo, MTX -- methotrexate, IFX -- infliximab, ETN -- etanercept, ADA -- adalimumab, GOL -- golimumab, TCZ -- tocilizumab, ABT -- abatacept, CZP -- clonazepam, cDMARDs -- traditional synthetic disease modifying antirheumatic drugs, ACR -- American College of Rheumatology, AEs -- adverse events, SAEs -- serious adverse events.

Remission {#sec3.6}
---------

The efficacy endpoint of remission was evaluated among 11 treatments as displayed in the upper panel of [Table III](#t0003){ref-type="table"}. It could be observed that TCZ and TCZ + MTX were significantly better than ABT + MTX (OR = 0.06, 95% CrI: 0.01--0.45; OR = 0.15, 95% CrI: 0.03--0.87), cDMARDs (OR = 0.01, 95% CrI: 0.01--0.07; OR = 0.04, 95% CrI: 0.01--0.11), ETN (OR = 0.03, 95% CrI: 0.01--0.32; OR = 0.07, 95% CrI: 0.01--0.64), ETN + MTX (OR = 0.05, 95% CrI: 0.01--0.34; OR = 0.13, 95% CrI: 0.02--0.65), GOL + MTX (OR = 0.08, 95% CrI: 0.01--0.55; OR = 0.22, 95% CrI: 0.05--0.98) and IFX + MTX (OR = 0.05, 95% CrI: 0.01--0.44; OR = 0.15, 95% CrI: 0.02--0.86) in disease remission. However, there was no particular evidence to confirm which one of TCZ and TCZ + MTX was better. ABT + MTX (OR = 0.25, 95% CrI: 0.06--0.97), ETN + MTX (OR = 0.29, 95% CrI: 0.08--0.98) and GOL + MTX (OR = 0.18, 95% CrI: 0.06--0.50) also presented greater remission of pain compared to cDMARDs. Additionally, GOL (OR = 0.05, 95% CrI: 0.01--0.66) was less efficacious than TCZ.

Adverse events (AEs) {#sec3.7}
--------------------

The safety outcomes are shown in [Table IV](#t0004){ref-type="table"}. Statistically, ABT (OR = 1.86, 95% CrI: 1.03--3.42), ADA (OR = 2.10, 95% CrI: 1.32--3.25) and CZP (OR = 2.01, 95% CrI: 1.25--3.29) presented a higher risk of AEs than PBO. ADA was more likely to cause adverse events than ADA + MTX (OR = 2.10, 95% CrI: 1.02--4.48), cDMARDs (OR = 2.59, 95% CrI: 1.35--5.00), CZP + MTX (OR = 2.08, 95% CrI: 1.01--4.31), ETN + MTX (OR = 2.10, 95% CrI: 1.08--4.14), GOL (OR = 2.51, 95% CrI: 1.04--5.99) and PBO (OR = 2.10, 95% CrI: 1.32--3.25). In comparison with ETN + MTX (OR = 2.01, 95% CrI: 1.01--4.10) and GOL (OR = 2.44, 95% CrI: 1.00--5.81) more patients taking CZP dropped out due to AEs. Moreover, the safety of cDMARDs for adverse events was superior to CZP (OR = 0.40, 95% CrI: 0.20--0.79), ETN (OR = 0.62, 95% CrI: 0.43--0.87), IFX + MTX (OR = 0.73, 95% CrI: 0.52--0.98), TCZ (OR = 0.65, 95% CrI: 0.47--0.92) and TCZ + MTX (OR = 0.69, 95% CrI: 0.53--0.90).

###### 

Odds ratio estimates with 95% credible intervals of AEs and SAEs for each comparison

  Endpoint    SAEs                                                                                                                                                                                                                                                                                                        
  ----------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  AEs         ABT                 ABT                 3.71 (0.88, 16.9)   2.39 (0.73, 8.67)   2.94 (0.66, 13.5)   2.94 (0.73, 12.3)   0.60 (0.12, 3.03)   1.82 (0.41, 8.76)   1.88 (0.45, 7.92)   2.29 (0.54, 9.49)   2.61 (0.38, 17.6)   1.31 (0.25, 6.55)   2.69 (0.63, 12.2)   2.36 (0.73, 8.41)   1.84 (0.46, 7.92)   2.12 (0.50, 9.49)
  ABT + MTX   1.77 (0.76, 4.26)   ABT + MTX           0.64 (0.24, 1.70)   0.80 (0.45, 1.28)   0.80 (0.51, 1.17)   0.16 (0.04, 0.66)   0.51 (0.24, 0.99)   0.51 (0.25, 0.92)   0.62 (0.32, 1.07)   0.68 (0.17, 2.64)   0.35 (0.14, 0.78)   0.73 (0.41, 1.25)   0.64 (0.25, 1.62)   0.50 (0.24, 0.96)   0.57 (0.30, 1.02)   
  ADA         0.89 (0.48, 1.63)   0.50 (0.23, 1.05)   ADA                 1.23 (0.44, 3.42)   1.25 (0.51, 2.94)   0.26 (0.08, 0.74)   0.78 (0.27, 2.25)   0.79 (0.32, 1.79)   0.96 (0.38, 2.27)   1.07 (0.23, 5.00)   0.55 (0.18, 1.67)   1.13 (0.41, 2.97)   0.99 (0.63, 1.60)   0.76 (0.32, 1.80)   0.88 (0.34, 2.25)   
  ADA + MTX   1.86 (0.82, 4.48)   1.05 (0.68, 1.65)   2.10 (1.02, 4.48)   ADA + MTX           1 (0.6, 1.68)       0.21 (0.05, 0.86)   0.63 (0.29, 1.38)   0.64 (0.31, 1.27)   0.78 (0.39, 1.46)   0.87 (0.21, 3.49)   0.44 (0.17, 1.06)   0.91 (0.48, 1.77)   0.81 (0.31, 2.14)   0.62 (0.30, 1.32)   0.71 (0.36, 1.42)   
  cDMARDs     2.29 (1.08, 5.10)   1.28 (0.90, 1.90)   2.59 (1.35, 5.00)   1.23 (0.85, 1.75)   cDMARDs             0.21 (0.05, 0.78)   0.63 (0.35, 1.12)   0.64 (0.38, 1.02)   0.78 (0.50, 1.14)   0.86 (0.22, 3.13)   0.44 (0.20, 0.89)   0.91 (0.59, 1.39)   0.80 (0.35, 1.88)   0.63 (0.36, 1.06)   0.71 (0.45, 1.12)   
  CZP         0.92 (0.42, 1.99)   0.52 (0.24, 1.13)   1.05 (0.53, 1.97)   0.50 (0.22, 1.05)   0.40 (0.20, 0.79)   CZP                 3.03 (0.72, 13.9)   3.13 (0.81, 12.4)   3.78 (0.97, 14.2)   4.31 (0.66, 25.5)   2.14 (0.45, 9.58)   4.44 (1.09, 18.2)   3.86 (1.48, 11.5)   3.03 (0.82, 10.9)   3.49 (0.89, 13.6)   
  CZP + MTX   1.84 (0.81, 4.35)   1.04 (0.64, 1.68)   2.08 (1.01, 4.31)   1.00 (0.61, 1.58)   0.81 (0.58, 1.11)   1.99 (0.93, 4.39)   CZP + MTX           1.01 (0.46, 2.14)   1.22 (0.59, 2.46)   1.38 (0.34, 5.53)   0.70 (0.27, 1.75)   1.45 (0.71, 3.00)   1.28 (0.45, 3.49)   0.98 (0.45, 2.20)   1.13 (0.54, 2.39)   
  ETN         1.42 (0.65, 3.16)   0.80 (0.47, 1.30)   1.60 (0.82, 3.10)   0.76 (0.45, 1.23)   0.62 (0.43, 0.87)   1.54 (0.76, 3.06)   0.77 (0.47, 1.21)   ETN                 1.21 (0.76, 1.92)   1.36 (0.33, 5.31)   0.69 (0.28, 1.63)   1.43 (0.75, 2.83)   1.26 (0.57, 2.92)   0.98 (0.49, 1.97)   1.13 (0.58, 2.23)   
  ETN + MTX   1.86 (0.86, 4.18)   1.05 (0.68, 1.63)   2.10 (1.08, 4.14)   1.00 (0.64, 1.54)   0.81 (0.64, 1.04)   2.01 (1.01, 4.10)   1.00 (0.68, 1.52)   1.31 (0.96, 1.86)   ETN + MTX           1.13 (0.27, 4.35)   0.57 (0.23, 1.32)   1.19 (0.66, 2.20)   1.03 (0.45, 2.51)   0.80 (0.42, 1.57)   0.92 (0.52, 1.73)   
  GOL         2.23 (0.86, 5.81)   1.26 (0.64, 2.46)   2.51 (1.04, 5.99)   1.20 (0.61, 2.27)   0.97 (0.55, 1.68)   2.44 (1.00, 5.81)   1.21 (0.63, 2.27)   1.57 (0.82, 3.03)   1.20 (0.65, 2.18)   GOL                 0.51 (0.15, 1.55)   1.06 (0.27, 3.90)   0.91 (0.21, 4.48)   0.72 (0.18, 2.83)   0.83 (0.21, 3.22)   
  GOL + MTX   1.79 (0.79, 4.18)   1.00 (0.63, 1.62)   2.01 (0.99, 4.18)   0.96 (0.59, 1.51)   0.78 (0.58, 1.05)   1.93 (0.92, 4.10)   0.96 (0.63, 1.51)   1.26 (0.80, 2.03)   0.96 (0.66, 1.40)   0.80 (0.47, 1.40)   GOL + MTX           2.08 (0.93, 4.95)   1.80 (0.63, 5.58)   1.42 (0.58, 3.53)   1.63 (0.70, 3.86)   
  IFX + MTX   1.65 (0.73, 3.94)   0.94 (0.59, 1.45)   1.86 (0.90, 3.90)   0.90 (0.54, 1.39)   0.73 (0.52, 0.98)   1.79 (0.84, 3.82)   0.90 (0.57, 1.40)   1.17 (0.74, 1.88)   0.90 (0.59, 1.31)   0.75 (0.39, 1.40)   0.93 (0.59, 1.40)   IFX + MTX           0.88 (0.35, 2.25)   0.68 (0.34, 1.34)   0.78 (0.43, 1.45)   
  PBO         1.86 (1.03, 3.42)   1.04 (0.57, 1.90)   2.10 (1.32, 3.25)   1.01 (0.54, 1.79)   0.81 (0.50, 1.31)   2.01 (1.25, 3.29)   1.00 (0.56, 1.80)   1.31 (0.80, 2.16)   1.00 (0.60, 1.63)   0.83 (0.40, 1.75)   1.04 (0.58, 1.82)   1.12 (0.63, 1.99)   PBO                 0.77 (0.34, 1.70)   0.89 (0.36, 2.12)   
  TCZ         1.51 (0.73, 3.32)   0.84 (0.52, 1.40)   1.70 (0.91, 3.19)   0.81 (0.50, 1.31)   0.65 (0.47, 0.92)   1.62 (0.86, 3.16)   0.81 (0.52, 1.31)   1.05 (0.70, 1.68)   0.80 (0.57, 1.17)   0.68 (0.36, 1.31)   0.84 (0.54, 1.32)   0.90 (0.58, 1.46)   0.81 (0.53, 1.27)   TCZ                 1.15 (0.66, 2.03)   
  TCZ + MTX   1.58 (0.74, 3.60)   0.89 (0.58, 1.42)   1.80 (0.91, 3.53)   0.85 (0.54, 1.32)   0.69 (0.53, 0.90)   1.72 (0.87, 3.49)   0.85 (0.58, 1.31)   1.12 (0.76, 1.73)   0.85 (0.61, 1.19)   0.71 (0.39, 1.34)   0.90 (0.60, 1.32)   0.95 (0.64, 1.46)   0.85 (0.53, 1.43)   1.06 (0.76, 1.48)   TCZ + MTX           

PBO -- placebo, MTX -- methotrexate, IFX -- infliximab, ETN -- etanercept, ADA -- adalimumab, GOL -- golimumab, TCZ -- tocilizumab, ABT -- abatacept, CZP -- clonazepam, cDMARDs -- traditional synthetic disease modifying antirheumatic drugs, ACR -- American College of Rheumatology, AEs -- adverse events, SAEs -- serious adverse events.

Serious adverse events (SAEs) {#sec3.8}
-----------------------------

The comparison of SAEs for all the treatments is displayed in the upper panel of [Table IV](#t0004){ref-type="table"}. CZP (OR = 3.86, 95% CrI: 1.48--11.5) presented a worse performance than PBO (OR = 0.26, 95% CrI: 0.09--0.68), INF + MTX (OR = 0.23, 95% CrI: 0.06--0.91), cDMARDs (OR = 0.21, 95% CrI: 0.05--0.78), ADA + MTX (OR = 0.21, 95% CrI: 0.05--0.86), ADA (OR = 0.26, 95% CrI: 0.08--0.74) and ABT + MTX (OR = 0.16, 95% CrI: 0.04--0.66). In contrast, ABT + MTX was more efficacious in reducing the SAEs in comparison with CZP + MTX (OR = 0.51, 95% CrI: 0.24--0.99), ETN (OR = 0.51, 95% CrI: 0.25--0.92), GOL + MTX (OR = 0.35, 95% CrI: 0.14--0.78) and TCZ (OR = 0.50, 95% CrI: 0.24--0.96). Furthermore, cDMARDs (OR = 0.44, 95% CrI: 0.20--0.89) worked better than GOL + MTX in withdrawal due to SAEs.

Relative ranking analysis {#sec3.9}
-------------------------

Relative ranking of the treatments is assessed by SUCRA in [Table V](#t0005){ref-type="table"}. Since CZP + MTX not only had high efficacy in ACR20 (83.3%), ACR50 (84.2%) and ACR70 (75.1%) but also performed well in AEs and SAEs, we recommend CZP + MTX as the optimal drug therapy. Another alternative was TCZ + MTX for the same reason. By contrast, ABT was regarded as the worst choice in treating RA because of its low probability in efficacy outcomes (ACR20: 10.8%, ACR50 = 2.4%, ACR70 = 20.0%) and safety outcomes (AEs = 14.8%, SAEs = 17.2%). Also, cDMARDs are not recommended due to their low efficacy, though their safety seemed to be superior.

###### 

Relative ranking of the treatments assessed by surface under cumulative ranking curve area

  Treatments   ACR20   ACR50   ACR70   Remission   AEs     SAEs
  ------------ ------- ------- ------- ----------- ------- -------
  ABT          0.108   0.239   0.200   --          0.148   0.172
  ABT + MTX    0.510   0.564   0.605   0.402       0.549   0.852
  ADA          0.392   0.375   0.326   0.617       0.077   0.551
  ADA + MTX    0.554   0.722   0.620   0.428       0.606   0.693
  cDMARDs      0.108   0.084   0.089   0.050       0.862   0.727
  CZP          0.818   0.796   0.882   --          0.099   0.051
  CZP + MTX    0.833   0.842   0.751   --          0.602   0.365
  ETN          0.359   0.307   0.358   0.220       0.295   0.356
  ETN + MTX    0.634   0.611   0.597   0.364       0.556   0.506
  GOL          0.303   0.332   0.332   0.360       0.747   0.567
  GOL + MTX    0.594   0.660   0.561   0.501       0.555   0.186
  IFX + MTX    0.547   0.546   0.511   0.385       0.466   0.637
  PBO          0.023   0.004   0.005   --          0.613   0.545
  TCZ          0.532   0.609   0.470   0.890       0.352   0.346
  TCZ + MTX    0.685   0.809   0.693   0.784       0.407   0.445

PBO -- placebo, MTX -- methotrexate, IFX -- infliximab, ETN -- etanercept, ADA -- adalimumab, GOL -- golimumab, TCZ -- tocilizumab, ABT -- abatacept, CZP -- clonazepam, cDMARDs -- traditional synthetic disease modifying antirheumatic drugs, ACR -- American College of Rheumatology, AEs -- adverse events, SAEs -- serious adverse events.

Consistency test {#sec3.10}
----------------

The node-splitting method was used to evaluate the consistency level between direct and indirect evidence. *P-*values \< 0.05 implied the existence of a significant inconsistency. As listed in [Table VI](#t0006){ref-type="table"}, a significant inconsistency did exist in the analysis of remission and AEs. As for remission, obvious inconsistency was found in the comparisons between TCZ and cDMARDs (*p* = 0.013), TCZ + MTX and cDMARDs (*p* = 0.015), as well as TCZ + MTX and TCZ (*p* = 0.019). On the other hand, no consistency between ETN + MTX and cDMARDs (*p* \< 0.001), TCZ and ETN + MTX (*p* = 0.034), TCZ + MTX and ETN + MTX (*p* = 0.025) was demonstrated when comparing them with AEs. The results of the consistency test are also visually presented in [Figure 3](#f0003){ref-type="fig"} with net heat plots, which indicated the same results as in [Table VI](#t0006){ref-type="table"}.

###### 

Results of consistency analysis by node-splitting plot

  Endpoint                  Comparison                Direct OR (95% CI)   Indirect OR (95% CrI)   Network OR (95% CrI)   *P*-value
  ------------------------- ------------------------- -------------------- ----------------------- ---------------------- -----------
  ACR20                     ADA + MTX vs. ABT + MTX   1.10 (0.35, 3.50)    1.10 (0.48, 2.70)       1.10 (0.53, 2.10)      0.899
  cDMARDs vs. ABT + MTX     0.34 (0.17, 0.68)         0.29 (0.07, 1.10)    0.31 (0.17, 0.56)       0.819                  
  cDMARDs vs. ADA + MTX     0.29 (0.16, 0.52)         0.31 (0.08, 1.10)    0.29 (0.17, 0.49)       0.928                  
  ETN vs. cDMARDs           2.50 (1.00, 6.10)         2.40 (1.00, 5.90)    2.50 (1.40, 4.60)       0.963                  
  ETN + MTX vs. cDMARDs     3.80 (2.50, 5.70)         4.70 (1.30, 15.0)    3.80 (2.60, 5.70)       0.723                  
  ETN + MTX vs. ETN         1.50 (0.86, 2.90)         1.20 (0.27, 4.90)    1.50 (0.89, 2.70)       0.751                  
  IFX + MTX vs. ABT + MTX   0.72 (0.22, 2.40)         1.30 (0.53, 3.20)    1.10 (0.51, 2.30)       0.425                  
  IFX + MTX vs. cDMARDs     3.50 (2.00, 5.80)         3.90 (0.52, 26.0)    3.50 (2.00, 5.60)       0.933                  
  IFX + MTX vs. ETN + MTX   1.00 (0.15, 7.30)         0.88 (0.46, 1.70)    0.90 (0.47, 1.70)       0.871                  
  PBO vs. ADA               0.22 (0.12, 0.38)         0.41 (0.10, 1.70)    0.23 (0.13, 0.40)       0.423                  
  PBO vs. ETN               0.22 (0.10, 0.48)         0.29 (0.08, 1.10)    0.23 (0.13, 0.45)       0.691                  
  TCZ vs. ADA               1.90 (0.53, 6.20)         1.00 (0.34, 2.70)    1.30 (0.62, 2.90)       0.413                  
  TCZ vs. cDMARDs           3.40 (1.40, 8.50)         3.30 (1.30, 8.40)    3.30 (1.80, 6.40)       0.950                  
  TCZ vs. PBO               3.50 (1.10, 11.0)         7.70 (3.10, 18.0)    5.60 (2.80, 12.0)       0.274                  
  TCZ + MTX vs. cDMARDs     4.00 (2.40, 7.00)         4.80 (1.10, 21.0)    4.20 (2.50, 6.90)       0.818                  
  TCZ + MTX vs. TCZ         1.40 (0.60, 3.20)         0.94 (0.35, 2.90)    1.30 (0.65, 2.50)       0.574                  
  ACR50                     ADA + MTX vs. ABT + MTX   1.10 (0.42, 2.80)    1.40 (0.59, 3.00)       1.20 (0.63, 2.30)      0.741
  cDMARDs vs. ABT + MTX     0.29 (0.16, 0.56)         0.22 (0.07, 0.74)    0.26 (0.15, 0.45)       0.679                  
  cDMARDs vs. ADA + MTX     0.21 (0.12, 0.35)         0.24 (0.08, 0.82)    0.21 (0.13, 0.36)       0.789                  
  ETN vs. cDMARDs           2.20 (0.96, 4.80)         3.00 (1.40, 6.80)    2.50 (1.50, 4.50)       0.565                  
  ETN + MTX vs. cDMARDs     4.30 (2.90, 6.50)         2.90 (0.92, 9.20)    4.10 (2.80, 6.20)       0.520                  
  ETN + MTX vs. ETN         1.50 (0.89, 2.60)         1.80 (0.45, 7.00)    1.60 (0.97, 2.60)       0.834                  
  IFX + MTX vs. ABT + MTX   0.88 (0.30, 2.50)         1.10 (0.45, 2.40)    0.98 (0.51, 1.90)       0.776                  
  IFX + MTX vs. cDMARDs     3.60 (2.10, 6.00)         5.80 (0.84, 41.0)    3.80 (2.40, 6.00)       0.630                  
  IFX + MTX vs. ETN + MTX   1.40 (0.24, 9.40)         0.87 (0.47, 1.60)    0.93 (0.52, 1.60)       0.606                  
  PBO vs. ADA               0.17 (0.09, 0.30)         0.41 (0.10, 1.40)    0.19 (0.11, 0.32)       0.223                  
  PBO vs. ETN               0.21 (0.10, 0.47)         0.20 (0.06, 0.64)    0.21 (0.10, 0.40)       0.920                  
  TCZ vs. ADA               2.40 (0.83, 6.90)         0.98 (0.37, 2.60)    1.50 (0.71, 3.00)       0.199                  
  TCZ vs. cDMARDs           3.50 (1.50, 8.30)         4.40 (1.90, 9.80)    4.10 (2.30, 7.40)       0.710                  
  TCZ vs. PBO               5.00 (1.90, 14.0)         9.80 (4.40, 22.0)    7.70 (4.00, 15.0)       0.299                  
  TCZ + MTX vs. cDMARDs     4.60 ( 3.00, 7.20)        9.10 (2.70, 33.0)    5.30 (3.40, 8.30)       0.299                  
  TCZ + MTX vs. TCZ         1.60 (0.84, 2.90)         0.73 (0.29, 1.90)    1.30 (0.71, 2.30)       0.166                  
  ACR70                     ADA + MTX vs. ABT + MTX   0.95 (0.27, 2.90)    1.10 (0.39, 3.20)       1.00 (0.46, 2.20)      0.800
  cDMARDs vs. ABT + MTX     0.19 (0.08, 0.42)         0.16 (0.04, 0.69)    0.19 (0.09, 0.37)       0.809                  
  cDMARDs vs. ADA + MTX     0.18 (0.08, 0.36)         0.22 (0.05, 0.92)    0.18 (0.09, 0.35)       0.755                  
  ETN vs. cDMARDs           2.60 (1.00, 8.00)         4.40 (1.70, 13.0)    3.30 (1.70, 6.60)       0.463                  
  ETN + MTX vs. cDMARDs     5.20 (3.20, 9.50)         6.80 (1.10, 46.0)    5.00 (3.20, 8.90)       0.770                  
  ETN + MTX vs. ETN         1.60 (0.83, 2.80)         0.79 (0.07, 6.90)    1.60 (0.88, 2.70)       0.548                  
  IFX + MTX vs. ABT + MTX   1.20 (0.32, 4.30)         0.58 (0.21, 1.60)    0.85 (0.38, 1.90)       0.355                  
  IFX + MTX vs. cDMARDs     3.90 (2.10, 7.70)         5.30 (0.13, 230)     4.50 (2.40, 8.70)       0.856                  
  IFX + MTX vs. ETN + MTX   1.0 0(0.02, 33.0)         0.86 (0.38, 2.00)    0.89 (0.40, 1.80)       0.901                  
  PBO vs. ADA               0.12 (0.05, 0.27)         0.31 (0.07, 1.40)    0.15 (0.08, 0.29)       0.238                  
  PBO vs. ETN               0.08 (0.01, 0.38)         0.17 (0.04, 0.64)    0.13 (0.04, 0.34)       0.478                  
  TCZ vs. ADA               2.20 (0.70, 7.10)         0.85 (0.22, 3.60)    1.50 (0.58, 3.60)       0.299                  
  TCZ vs. cDMARDs           3.20 (1.10, 8.80)         5.40 (1.50, 18.0)    4.10 (1.90, 8.40)       0.494                  
  TCZ vs. PBO               4.80 (1.50, 15.0)         18.0 (6.30, 59.0)    10.0 (4.10, 25.0)       0.085                  
  TCZ + MTX vs. cDMARDs     5.60 (3.30, 9.60)         7.70 (1.70, 30.0)    6.10 (3.50, 11.0)       0.661                  
  TCZ + MTX vs. TCZ         1.60 (0.83, 3.50)         0.90 (0.30, 3.00)    1.50 (0.73, 3.20)       0.396                  
  Remission                 IFX + MTX vs. ABT + MTX   1.10 (0.10, 11.0)    0.66 (0.04, 13.0)       0.94 (0.16, 5.00)      0.749
  TCZ vs. cDMARDs           360 (73.0,1800)           12.0 (2.60, 71.0)    70.0 (13.0,380)         0.013                  
  TCZ + MTX vs. cDMARDs     15.0 (7.10, 37.0)         430 (47.0, 3500)     26.0 (9.10, 78.0)       0.015                  
  TCZ + MTX vs. TCZ         1.30 (0.34, 4.60)         0.04 (0.01, 0.29)    0.38 (0.07, 1.70)       0.019                  
  AEs                       ADA + MTX vs. ABT + MTX   0.84 (0.41, 1.60)    1.00 (0.57, 1.80)       0.95 (0.60, 1.50)      0.628
  cDMARDs vs. ABT + MTX     0.83 (0.53, 1.30)         0.65 (0.30, 1.50)    0.77 (0.53, 1.10)       0.611                  
  cDMARDs vs. ADA + MTX     0.78 (0.50, 1.20)         0.96 (0.42, 2.20)    0.81 (0.57, 1.20)       0.635                  
  ETN vs. cDMARDs           2.00 (1.20, 3.50)         1.30 (0.85, 2.20)    1.60 (1.20, 2.40)       0.236                  
  ETN + MTX vs. cDMARDs     1.00 (0.79, 1.30)         2.70 (1.70, 4.30)    1.20 (0.97, 1.60)       \< 0.001               
  ETN + MTX vs. ETN         0.86 (0.55, 1.20)         0.47 (0.24, 0.93)    0.77 (0.53, 1.10)       0.154                  
  IFX + MTX vs. ABT + MTX   1.20 (0.58, 2.30)         0.99 (0.56, 1.80)    1.10 (0.67, 1.70)       0.679                  
  PBO vs. ETN               0.76 (0.37, 1.50)         0.76 (0.35, 1.50)    0.77 (0.45, 1.20)       0.996                  
  TCZ vs. cDMARDs           1.60 (0.92, 2.70)         1.40 (0.83, 2.20)    1.50 (1.10, 2.10)       0.708                  
  TCZ vs. ETN + MTX         0.68 (0.36, 1.30)         1.50 (0.97, 2.40)    1.20 (0.85, 1.80)       0.034                  
  TCZ vs. PBO               1.20 (0.75, 2.20)         1.20 (0.51, 2.80)    1.20 (0.79, 2.00)       0.996                  
  TCZ + MTX vs. cDMARDs     1.60 (1.20, 2.10)         0.94 (0.54, 1.60)    1.40 (1.10, 1.80)       0.093                  
  TCZ + MTX vs. ETN + MTX   0.61 (0.30, 1.10)         1.40 (0.99, 2.00)    1.20 (0.84, 1.60)       0.025                  
  TCZ + MTX vs. TCZ         0.86 (0.58, 1.30)         1.00 (0.53, 1.90)    0.95 (0.68, 1.30)       0.619                  
  SAEs                      ADA + MTX vs. ABT + MTX   1.20 (0.58, 2.40)    1.30 (0.61, 3.70)       1.20 (0.77, 2.20)      0.919
  cDMARDs vs. ABT + MTX     1.30 (0.80, 2.30)         1.20 (0.42, 3.00)    1.20 (0.83, 1.90)       0.885                  
  cDMARDs vs. ADA + MTX     0.97 (0.45, 1.90)         1.00 (0.45, 2.60)    0.99 (0.59, 1.70)       0.936                  
  ETN vs. ADA               1.30 (0.32, 4.30)         1.40 (0.43, 4.70)    1.30 (0.53, 3.40)       0.904                  
  ETN vs. cDMARDs           1.70 (0.92, 3.60)         1.40 (0.55, 4.00)    1.60 (0.97, 2.7)        0.760                  
  ETN + MTX vs. cDMARDs     1.30 (0.88, 2.20)         1.70 (0.26,11.0)     1.30 (0.88,2.10)        0.829                  
  ETN + MTX vs. ETN         0.81 (0.52, 1.30)         0.82 (0.18, 4.60)    0.82 (0.50, 1.30)       1.000                  
  IFX + MTX vs. ABT + MTX   2.40 (0.96, 6.60)         1.00 (0.56, 2.00)    1.30 (0.82, 2.40)       0.145                  
  IFX + MTX vs. ETN + MTX   1.30 (0.50, 3.80)         1.30 (0.34, 4.90)    1.30 (0.61, 3.30)       0.989                  
  PBO vs. ADA               1.00 (0.62, 1.70)         0.90 (0.16, 5.00)    1.00 (0.61, 1.50)       0.875                  
  PBO vs. ETN               0.61 (0.07, 4.30)         0.82 (0.31, 2.10)    0.76 (0.28, 1.70)       0.780                  
  TCZ vs. cDMARDs           1.70 (0.81,3.50)          1.40 (0.55,4.40)     1.60 (0.93,2.80)        0.839                  
  TCZ vs. PBO               0.85 (0.39, 1.80)         0.91 (0.37, 2.30)    0.88 (0.48, 1.50)       0.910                  
  TCZ + MTX vs. cDMARDs     1.40 (0.87, 2.40)         1.50 (0.35, 6.30)    1.40 (0.90, 2.20)       0.934                  

PBO -- placebo, MTX -- methotrexate, IFX -- infliximab, ETN -- etanercept, ADA -- adalimumab, GOL -- golimumab, TCZ -- tocilizumab, ABT -- abatacept, CZP -- clonazepam, cDMARDs -- traditional synthetic disease modifying antirheumatic drugs, ACR -- American College of Rheumatology, AEs: adverse events, SAEs -- serious adverse events.

![Results of consistency analysis by heat plot. Inconsistency between direct and indirect evidence was assessed using the net heat plots, which visually displayed the inconsistency level with different colors. The more vibrant the color was, the more serious was the indicated inconsistency\
A -- TCZ + MTX, B -- TCZ, C -- PBO, D -- IFX + MTX, E -- GOL + MTX, F -- GOL, G -- ETN + MTX, H -- ETN, I -- CZP + MTX, J -- CZP, K -- cDMARDs, L -- ADA + MTX, M -- ADA, N -- ABT + MTX, O -- ABT.](AMS-15-31923-g003){#f0003}

Publication bias {#sec3.11}
----------------

The estimate of publication bias was performed by the symmetry characteristics of the dots representing included trials with different colors in the funnel plots. According to [Figure 4](#f0004){ref-type="fig"}, all of the funnel plots were focused in the triangle funnel areas in left and right directions, which suggested that the distribution of dots verified no significant publication bias or small study effect among the trials in ACR20, ACR50, ACR70, AEs, SAEs and remission.

![Publication bias of different outcomes](AMS-15-31923-g004){#f0004}

Evaluation of the methodological quality of eligible studies {#sec3.12}
------------------------------------------------------------

The Jadad scale was used to appraise the methodological quality of included studies, and the scores of the Jadad scale of each individual study are shown in [Table VII](#t0007){ref-type="table"}. As shown in [Table VII](#t0007){ref-type="table"}, most scores are greater than 4, which indicates that those included studies are of high quality.

###### 

Jadad scale of 67 included studies

  Author, year                     Randomized   Blinded   Withdrawal
  -------------------------------- ------------ --------- ------------
  Abe *et al.*, 2006               2            2         0
  Bae *et al.*, 2013               2            0         0
  Kim *et al.*, 2012               2            0         1
  Combe *et al.*, 2006             2            2         1
  Combe *et al.*, 2016             2            2         1
  Dougados *et al.*, 2013          2            2         1
  Kameda *et al.*, 2014            2            0         0
  Jobanputra *et al.*, 2012        2            0         1
  Kay *et al.*, 2008               2            2         0
  Kim *et al.*, 2007               2            2         1
  Kremer *et al.*, 2011            2            2         1
  Kremer *et al.*, 2006            2            2         0
  Lan *et al.*, 2004               2            2         0
  Mathias *et al.*, 2000           2            2         0
  Moreland *et al.*, 1999          2            2         1
  Miyasaka *et al.*, 2008          2            2         1
  Nishimoto *et al.*, 2009         2            2         1
  O'Dell *et al.*, 2013            2            2         1
  O'Dell *et al.*, 2012            2            2         1
  Nishimoto *et al.*, 2007         2            1         1
  Tanake *et al.*, 2016            2            2         0
  Schiff *et al.*, 2008            2            2         0
  Van Riel *et al.*, 2006          2            0         0
  Van Riel *et al.*, 2008          2            0         1
  Van Vollenhoven *et al.*, 2011   2            2         0
  Weinblatt *et al.*, 2003         2            2         1
  Weinblatt *et al.*, 2006         2            2         1
  Westhovens *et al.*, 2006        2            1         0
  Zhang *et al.*, 2006             2            2         1
  Keystone *et al.*, 2012          2            2         1
  Smolen *et al.*, 2009            2            2         1
  Smolen *et al.*, 2008            2            2         1
  Gabay *et al.*, 2012             2            2         0
  Genovese *et al.*, 2008          2            2         1
  Yamamoto *et al.*, 2014          2            2         1
  Schiff *et al.*, 2014            2            1         0
  Weinblatt *et al.*, 2012         2            2         1
  Weinblatt *et al.*, 2003         2            2         1
  Fleischmann *et al.*, 2012       2            2         1
  Feischmann *et al.*, 2009        2            2         1
  Choy *et al.*, 2012              2            2         1
  Keystone *et al.*, 2009          2            2         0
  Chen *et al.*, 2009              2            2         0
  Keystone *et al.*, 2008          2            2         1
  Maini *et al.*, 2006             2            2         1
  Maini *et al.*, 1999             2            2         1
  Vandeputte *et al.*, 2004        2            2         1
  Vandeputte *et al.*, 2003        2            2         1
  Klareskog *et al.*, 2004         2            2         0
  Lipsky *et al.*, 2000            2            0         0
  Kremer *et al.*, 2003            2            2         0
  Chen *et al.*, 2016              2            2         1
  Fleischmann *et al.*, 2014       2            2         0
  Machado *et al.*, 2014           2            0         0
  Kivitz *et al.*, 2014            2            2         1
  Kivitz *et al.*, 2013            2            2         1
  Hobbs *et al.*, 2015             2            2         0
  Li *et al.*, 2015                2            2         1
  Conaghan *et al.*, 2013          2            2         1
  Keystome *et al.*, 2004          2            2         1
  Defilippis *et al.*, 2006        2            2         0
  Weinbaltt *et al.*, 2003         2            2         1
  Weinbaltt *et al.*, 1999         2            2         1
  Smolen *et al.*, 2011            2            2         1
  Strand *et al.*, 2011            2            2         1
  Moreland *et al.*, 1997          2            2         1
  Furst *et al.*, 2003             2            2         1

Each question was to be answered with either a yes or a no. Each yes would score a single point, each no zero points. Additional points were given if: The method of randomization was described in the paper, and that method was appropriate (1 extra point in the randomization part); the method of blinding was described, and it was appropriate (1 extra point in the blinding part).

Discussion {#sec4}
==========

Based on the data and information of included RCTs, our study aims to evaluate the efficacy and safety of 15 drug therapies for RA patients. All available direct and indirect evidence of various treatment options was analyzed and compared simultaneously by NMA, which has a great advantage over traditional MA and makes up for the lack of head-to-head comparisons \[[@cit0080]\]. Therefore, our studies are much more reliable than the other MAs or NMAs. Moreover, it is more reasonable to select 4 efficacy and 2 safety endpoints as the evaluation indexes. Although there are also some NMA studies on this topic, they mostly include two or three outcomes to be compared. For example, some researchers only select ACR20 as the efficacy outcome and AEs as the safety outcome \[[@cit0001]\], which is not comprehensive enough.

After a systematic analysis of 15 therapies for patients with RA from 56 RCTs, we prefer to recommend CZP + MTX as the best treatment due to it having the highest rankings in ACR20 (83.3%) and ACR50 (84.2%) response rates and relatively low risk of adverse events. TCZ + MTX is recommended as an alternative treatment due to its good performance in all efficacy and safety outcomes. ABT is considered as the worst therapy, and cDMARDs is also not recommended though its safety seemed to be superior.

Interestingly, among these 15 drug therapies, six are biologics and another six are different combinations of MTX and biologics, including comparisons between ABT and ABT + MTX, ADA and ADA + MTX, CZP and CZP + MTX, ETN and ETN + MTX, GOL and GOL + MTX as well as TCZ and TCZ + MTX. It is easy to find that in most cases the efficacy and safety of a biological agent plus MTX are superior to the corresponding biologic agent alone. For example, the SUCRAs of efficacy and safety outcomes for ABT are as follows: 10.8% (ACR20), 23.9% (ACR50), 20% (ACR70), 14.8% (AEs) and 17.2% (SAEs). By contrast, ABT + MTX is more efficacious and safer with corresponding SUCRAs of 51%, 56.4%, 60.5%, 54.9% and 85.2%. Previous researchers have also conducted direct comparisons between biologic monotherapy and a biological agent combined with MTX. For instance, Klareskog *et al.* demonstrated that the proportions of RA patients achieving ACR20, ACR50 and ACR70 were higher under the treatment of ETN + MTX than the ETN monotherapy. At week 52, about 85%, 69%, 43% and 35% of patients in the ETN + MTX group achieved ACR20, ACR50, ACR70 and remission compared with 76%, 48%, 24% and 16% in the ETN groups \[[@cit0081]\], which is in line with our results.

However, a closer observation reveals that there is an exception. GOL + MTX performs better in all efficacy outcomes than GOL as the other treatments of a biologic agent plus MTX, while it performed worse in AEs and SAEs. There are also studies which presented a different conclusion. Some studies published before presented no difference between two kinds of treatment groups. Patients with RA treated with ETN and those treated with ETN + MTX were similar in ACR20, ACR50 and ACR70 (71.0% vs. 67.1%, 41.9% vs. 40.1% and 17.4% vs. 18.4%, respectively). The rates of adverse events and serious adverse events were also similar \[[@cit0082]\]. Maini *et al.* arrived at the same conclusion in the comparison between TCZ + MTX and TCZ \[[@cit0083]\]. Thus, further research should be conducted to estimate whether MTX benefits biologic monotherapy or not.

Although we have made the study as comprehensive as possible, there are still some limitations. Firstly, despite the fact that the inclusion trials were all RCTs, the results of efficacy and safety comparisons among 15 drug therapies still showed some statistical inconsistency. Perhaps the RCTs with contradictions between direct and indirect evidence should be reconsidered. Secondly, though disease durations of these interventions ranged from 14 weeks to 54 weeks, 16 of them only had a follow-up time of less than 20 weeks. A short duration is not enough to judge the safety of treatment \[[@cit0001]\]. Thirdly, medication dose, treatment cost, patient compliance and other influential factors also affected trial homogeneity. To some extent, the improvement in patients with RA is related to the dose of drugs, which was neglected in this study \[[@cit0083]\]. Last but not least, different RCTs included in our research had different definitions of safety outcomes. There is still a shortage of clear definition of AEs and SAEs.

In conclusion, we regard CZP + MTX as the optimal choice for RA patients in clinical practice and TCZ + MTX as an alternative treatment. Conversely, both ABT and cDMARDs are not recommended. It is necessary to conduct long-term studies on patients with RA in order to provide a more complete assessment of diverse treatments and make a more judicious choice in clinical practice. In other words, we ought not only take into account clinical parameters such as ACR response rates and safety outcomes, but should also consider medication dose, treatment cost, patient compliance and so on. All efforts should be made to improve the life quality and health standard for patients with RA.
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